

**From:** William Edwards, Primus Pharmaceuticals  
**To:** AGO - High Cost Prescription Drugs  
**Subject:** Primus-New Drug Notice  
**Date:** September 29, 2021

To Whom It May Concern:

I write to report the launch of the brand name prescription drug Sernivo®.

The product Sernivo® (betamethasone dipropionate). Sernivo® is a brand name product. The NDC is 68040-0714-28. The strength of Sernivo® is 0.05%. The dosage form is an Emulsion spray. The drug product package size is 120 ML. The current WAC price is \$997.50.

We estimate that 45,000 prescriptions per product will be written per year across the United States. We do not have an estimate of the number of patients in Vermont. Our ANDA for this product was not granted breakthrough therapy designation or priority review.

These products were acquired in March of 2020. The products originally entered the market in 2017. The Introduction WAC for Sernivo® was \$859.95. The NDC that is included in this document is that of Primus Pharmaceuticals.

If any other information is required, please contact Bill Edwards by either telephone at 480-458-8620 or by email at WEdwards@primusrx.com.

Regards,

William M. Edwards



---